Universal monitoring of minimal residual disease in acute myeloid leukemia.

about

Universal monitoring of minimal residual disease in acute myeloid leukemia.

Item

http://www.wikidata.org/entity/Q55333539

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Universal monitoring of minimal residual disease in acute myeloid leukemia.

@en

Universal monitoring of minimal residual disease in acute myeloid leukemia.

@nl

type

Item

label

Universal monitoring of minimal residual disease in acute myeloid leukemia.

@en

Universal monitoring of minimal residual disease in acute myeloid leukemia.

@nl

prefLabel

Universal monitoring of minimal residual disease in acute myeloid leukemia.

@en

Universal monitoring of minimal residual disease in acute myeloid leukemia.

@nl

P1476

Universal monitoring of minimal residual disease in acute myeloid leukemia.

@en

P2093

Allen Eng-Juh Yeoh

http://www.w3.org/2001/XMLSchema#string

Dario Campana

http://www.w3.org/2001/XMLSchema#string

Elaine Coustan-Smith

http://www.w3.org/2001/XMLSchema#string

Guangchun Song

http://www.w3.org/2001/XMLSchema#string

James R Downing

http://www.w3.org/2001/XMLSchema#string

Jeffrey E Rubnitz

http://www.w3.org/2001/XMLSchema#string

Sheila Shurtleff

http://www.w3.org/2001/XMLSchema#string

Siew Peng Chen

http://www.w3.org/2001/XMLSchema#string

Wee Joo Chng

http://www.w3.org/2001/XMLSchema#string

P2860

Minimal residual disease-directed therapy in acute myeloid leukemia

Childhood acute myeloid leukaemia

FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?

Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML.

Assessment of Minimal Residual Disease in Standard-Risk AML.

Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells

Measurable residual disease testing in acute myeloid leukaemia.

Detection of minimal residual disease in acute leukemia by flow cytometry.

Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells.

The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells.

P31

scholarly article

P356

10.1172/JCI.INSIGHT.98561

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Ching-Hon Pui

P577

2018-05-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29720577

http://www.w3.org/2001/XMLSchema#string

P932

6012500

http://www.w3.org/2001/XMLSchema#string